{"id":"W2111592390","doi":"10.1158/1535-7163.mct-09-0868","title":"Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Sorafenib; Erlotinib; Medicine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Dosing; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146275,0.0008858083,0.00184539,0.0003271349,0.0005032675,0.0008135914,0.000561634,0.0004944731,0.00154422],"category_scores_gemma":[0.001343244,0.000283445,0.0007156879,0.000317583,0.0005843315,0.0005727998,0.0004731432,0.001601693,0.0006220061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005905793,"about_ca_system_score_gemma":0.0008965433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004261662,"about_ca_topic_score_gemma":0.0004874917,"domain_scores_codex":[0.9990839,0.000378656,0.00004731721,0.0001670806,0.000164428,0.0001586164],"domain_scores_gemma":[0.9987625,0.0002012789,0.0001832931,0.0002595295,0.0001162629,0.0004772496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2635809,0.0462382,0.2137359,0.0004751751,0.002051433,0.003510024,0.001365227,0.005259337,0.1836792,0.0004319973,0.006397725,0.273275],"study_design_scores_gemma":[0.03649254,0.5521132,0.3573365,0.0000521952,0.001673744,0.007587937,0.0004726864,0.005050652,0.02589015,0.0003140991,0.01292946,0.00008690034],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997621,0.0005752494,0.0004468664,0.00004616963,0.00001250709,0.0003278252,0.0003074292,0.00003453573,0.0006283829],"genre_scores_gemma":[0.9938625,0.0004399821,0.0009847592,0.0002210271,0.00007619226,0.0005528136,0.002824271,0.00003009934,0.001008399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002146275,"threshold_uncertainty_score":0.01135069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02369643222142025,"score_gpt":0.4094501007553262,"score_spread":0.3857536685339059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}